NS-2664
 | |
| Identifiers | |
|---|---|
| |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H14N4O |
| Molar mass | 326.359 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
NS-2664 (LS-193,048) is an anxiolytic drug with a novel chemical structure, developed by the small pharmaceutical company NeuroSearch. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic. NS-2664 is a potent but non-selective partial agonist at GABAA receptors, although with little efficacy at the α1 subtype and more at α2 and α3. It has potent anticonvulsant effects in animal studies, but a relatively short duration of action, and produces little sedative effects or physical dependence.[1]
References
- ^ Mirza NR, Nielsen EØ (March 2006). "Do subtype-selective gamma-aminobutyric acid A receptor modulators have a reduced propensity to induce physical dependence in mice?". The Journal of Pharmacology and Experimental Therapeutics. 316 (3): 1378–85. doi:10.1124/jpet.105.094474. PMID 16352707. S2CID 22700422.
 | This article about an anxiolytic is a stub. You can help Wikipedia by expanding it. |